26036 Federal Register / Vol. 60, No. 94 / Tuesday, May 16, 1995 / Notices

must be received at the Reserve Bank

indicated for the application or the

offices of the Board of Governors not

later than May 30, 1995.

A. Federal Reserve Bank of Cleveland

(John J. Wixted, Jr., Vice President) 1455

East Sixth Street, Cleveland, Ohio

44101:

1. Mellon Bank Corporation,

Pittsburgh, Pennsylvania; to acquire

Certus Financial Corporation, San

Francisco, California, and thereby

engage in providing investment and

advisory services, pursuant to §

225.25(b)(4) of the Board’s Regulation Y.

B. Federal Reserve Bank of St. Louis

(Randall C. Sumner, Vice President) 411

Locust Street, St. Louis, Missouri 63166:

1. Mountain Bancshares, Inc.,

Yellville, Arkansas; to acquire Financial

Institution Services, Inc., Green Forest,

Arkansas, and thereby engage in data

processing and data transmission

services for financial institutions,

pursuant to § 225.25(b)(7) of the Board’s

Regulation Y. The geographic scope for

these activities is the cities of Yellville,

Bull Shoals, and Flippin, Arkansas.

Board of Governors of the Federal Reserve

System, May 10, 1995.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 95–11999 Filed 5–15–95; 8:45 am]

BILLING CODE 6210–01–F

Larry F. Ness, et al.; Change in Bank

Control Notices; Acquisitions of

Shares of Banks or Bank Holding

Companies; Correction

This notice corrects the notices (FR

Doc. 95-11227) published on page 22580

of the issue for Monday, May 8, 1995.

Under the Federal Reserve Bank of

Minneapolis heading, the entry for Larry

F. Ness, is revised to read as follows:

A. Federal Reserve Bank of

Minneapolis (James M. Lyon, Vice

President) 250 Marquette Avenue,

Minneapolis, Minnesota 55480:

1. Larry F. Ness, Yankton, South

Dakota; to acquire an additional 26.39

percent, for a total of 45.78 percent, of

the voting shares of First Dakota

Financial Corporation, Yankton, South

Dakota, and thereby indirectly acquire

First Dakota National Bank, Yankton,

South Dakota.

Under the Federal Reserve Bank of

San Francisco heading, the entry for

John C. Bell, is revised to read as

follows:

B. Federal Reserve Bank of San

Francisco (Kenneth R. Binning,

Director, Bank Holding Company) 101

Market Street, San Francisco, California

94105:

1. John C. Bell; John C. Bell Family

Trust and K&G Trust, all of Studio City,

California; to acquire an additional 4.68

percent, for a total of 13.73 percent, of

the voting shares of Western Security

Bancorp, Burbank, California, and

thereby indirectly acquire Western

Security Bank, N.A., Burbank,

California.

Comments on these applications must

be received by May 22, 1995.

Board of Governors of the Federal Reserve

System, May 10, 1995.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 95–12000 Filed 5–15–95; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Advisory Committees; Notice of

Meetings

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: This notice announces

forthcoming meetings of public advisory

committees of the Food and Drug

Administration (FDA). This notice also

summarizes the procedures for the

meetings and methods by which

interested persons may participate in

open public hearings before FDA’s

advisory committees.

FDA has established an Advisory

Committee Information Hotline (the

hotline) using a voice-mail telephone

system. The hotline provides the public

with access to the most current

information on FDA advisory committee

meetings. The advisory committee

hotline, which will disseminate current

information and information updates,

can be accessed by dialing 1–800–741–

8138 or 301–443–0572. Each advisory

committee is assigned a 5-digit number.

This 5-digit number will appear in each

individual notice of meeting. The

hotline will enable the public to obtain

information about a particular advisory

committee by using the committee’s 5-

digit number. Information in the hotline

is preliminary and may change before a

meeting is actually held. The hotline

will be updated when such changes are

made.

MEETINGS: The following advisory

committee meetings are announced:

Endocrinologic and Metabolic Drugs

Advisory Committee

Date, time, and place. June 1, 1995, 8

a.m., Holiday Inn—Silver Spring, Plaza

Ballroom, 8777 Georgia Ave., Silver

Spring, MD.

Type of meeting and contact person.

Open public hearing, 8 a.m. to 9 a.m.,

unless public participation does not last

that long; open committee discussion, 9

a.m. to 5 p.m.; Kathleen R. Reedy,

Center for Drug Evaluation and Research

(HFD–9), Food and Drug

Administration, 5600 Fishers Lane,

Rockville, MD 20857, 301–443–5455,

FAX 301–443–0699, or FDA Advisory

Committee Information Hotline, 1–800–

741–8138 (301–443–0572 in the

Washington, DC area), Endocrinologic

and Metabolic Drugs Advisory

Committee, code 12536.

General function of the committee.

The committee reviews and evaluates

data on the safety and effectiveness of

marketed and investigational human

drugs for use in endocrine and

metabolic disorders.

Agenda—Open public hearing.

Interested persons may present data,

information, or views, orally or in

writing, on issues pending before the

committee. Those desiring to make

formal presentations should notify the

contact person before May 26, 1995, and

submit a brief statement of the general

nature of the evidence or arguments

they wish to present, the names and

addresses of proposed participants, and

an indication of the approximate time

required to make their comments.

Open committee discussion. The

committee will hear presentations and

discuss data submitted regarding the

safety and efficacy of acarbose, new

drug application 20–482, (Precose,

Bayer Corp.), for a non-insulin

dependent diabetes mellitus indication.

Working Group Meeting of the Food

Advisory Committee

Date, time, and place. June 7 and 8,

1995, 8:30 a.m., Days Inn—Downtown

Convention Center, 1201 K St. NW.,

Washington, DC.

Type of meeting and contact person.

Open working group discussion, June 7,

1995, 8:30 a.m. to 4 p.m.; open public

hearing, 4 p.m. to 5:30 p.m., unless

public participation does not last that

long; open working group discussion,

June 8, 1995, 8:30 a.m. to 12 m.; Lynn

A. Larsen, Center for Food Safety and

Applied Nutrition (HFS–5), Food and

Drug Administration, 200 C St. SW.,

Washington, DC 20204, 202–205–4727,

or Catherine M. DeRoever, Advisory

Committee Staff (HFS–22), 202–205–

4251, FAX 202–205–4970, or FDA